Poulton Stuart's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Sep 16, 2025
- Accession no.
- 0001193125-25-205046
- Filed
- Sep 16, 2025
- Trade date
- Sep 12-15, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.58K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poulton StuartCIK 0001942597 | Officer (EVP, Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | AGrant or awardAcquired | +888 | $0.00 | $0 | 28,111 | Direct | |
| Sep 15, 2025 | Common Stock | SSaleDisposed | −401 | $6.43 | −$2,578.43 | 27,710 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.